Merck to acquire Curon Biopharmaceutical’s CN201 in strategic oncology expansion
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a pivotal acquisition by agreeing to purchase CN201, ... Read More
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a pivotal acquisition by agreeing to purchase CN201, ... Read More